Abstract

Background Direct oral anticoagulants (DOACs) have revolutionised anticoagulant pharmacotherapy. However, DOAC-related medication incidents are known to be common. Objective To assess medication incidents associated with DOACs using an error theory and to analyse pharmacists’ contributions in minimising medication incidents in hospital in-patients. Setting A large University academic hospital in the West Midlands of England. Methods Medication incident data from the incident reporting system (48-months period) and pharmacists’ interventions data from the prescribing system (26-month period) relating to hospital in-patients were extracted. Reason’s Accident Causation Model was used to identify potential causality of the incidents. Pharmacists’ intervention data were thematically analysed. Main outcome measure (a) Frequency, type and potential causality of DOAC-related incidents; (b) nature of pharmacists’ interventions. Results A total of 812 reports were included in the study (124 medication incidents and 688 intervention reports). Missing drug/omission was the most common incident type (26.6%, n = 33) followed by wrong drug (16.1%, n = 20) and wrong dose/strength (11.3%, n = 14). A high majority (89.5%, n = 111) of medication incidents were caused by active failures. Patient discharge without anticoagulation supply and failure to restart DOACs post procedure/scan were commonly recurring themes. Pharmacists’ interventions most frequently related to changes in pharmacological strategy, including drug or dose changes (38.1%, n = 262). Impaired renal function was the most common reason for dose adjustments. Conclusion Prescribers’ active failure rather than system errors (i.e. latent failures) contributed to the majority of DOAC-related incidents. Reinforcement of guideline adherence, prescriber education, harnessing pharmacists’ roles and mandating renal function information in prescriptions are likely to improve patient safety.

Highlights

  • IntroductionAnticoagulants are first-line therapy for thromboembolic events

  • The traditionally used vitamin K antagonist (VKA), warfarin has been gradually replaced by direct oral anticoagulants (DOACs), previously known as novel oral anticoagulants (NOACs)

  • This study shows that the majority of the Direct oral anticoagulants (DOACs)-related incidents in the hospital in-patients occurred in the prescribing and administration stages of the medication process

Read more

Summary

Introduction

Anticoagulants are first-line therapy for thromboembolic events. They are indicated for prophylaxis and treatment of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and. International Journal of Clinical Pharmacy pulmonary embolism (PE). They are used to reduce the risk of secondary complications such as stroke in patients with atrial fibrillation (AF) [3, 4]. The traditionally used vitamin K antagonist (VKA), warfarin has been gradually replaced by direct oral anticoagulants (DOACs), previously known as novel oral anticoagulants (NOACs). Direct oral anticoagulants (DOACs) have revolutionised anticoagulant pharmacotherapy. DOACrelated medication incidents are known to be common

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call